Mark Newman

Chief Tech/Sci/R&D Officer at GEOVAX LABS, INC.

Net worth: - $ as of 2024-04-29

69 year

22 connections

Health Technology

Consumer Services

Technology Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Robert McNally	M	76	GEOVAX LABS, INC.	18 years
David Dodd	M	74	GEOVAX LABS, INC.	14 years
Mark Reynolds	M	62	GEOVAX LABS, INC.	18 years
Randal Chase	M	74	GEOVAX LABS, INC.	9 years
John Spencer	M	83	GEOVAX LABS, INC.	18 years
Dean Kollintzas	M	50	GEOVAX LABS, INC.	18 years
Nicole Lemerond	F	48	GEOVAX LABS, INC.	2 years
Kelly McKee	M	74	GEOVAX LABS, INC.	2 years
John Sharkey	M	67	GEOVAX LABS, INC.	2 years
Erica Raiden	F	-	GEOVAX LABS, INC.	2 years
Jayne Morgan	M	61	GEOVAX LABS, INC.	2 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Steven S. Antebi	M	80	GEOVAX LABS, INC.	2 years
Achim Kaufhold	M	66	Pharmexa A/S Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration	2 years
Ted Greene	M	81	Epimmune, Inc.	-
Georges Hibon	M	86	Epimmune, Inc.	-
Emile Loria	M	74	Epimmune, Inc.	4 years
William T. Comer	M	85	Epimmune, Inc.	11 years
Robert J. de Vaere	M	66	Epimmune, Inc.	5 years
Michael Grey	M	71	Epimmune, Inc.	-
Peter M. Tsolinas	M	87	GEOVAX LABS, INC.	2 years
Peter Nordkild	M	69	Pharmexa A/S Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration	2 years
Hans Henrik Chrois Christensen	M	59	Pharmexa A/S Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration	-

Statistics

Country	Connections	% of total
United States	19	86.36%
Denmark	3	13.64%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections